Oncorus racks up $61 mln Series A

Oncorus Inc, a new immuno-oncology company, has raised its Series A funding to $61 million as a result of an investment made by Astellas Pharma Venture Management LLC, the corporate venture unit of Astellas Pharma. The company's other investors include Deerfield Management, Arkin Bio Ventures and MPM.

North AmericaUSBriefs